Purchase Order 75N91021P00130

<p>The National Cancer Institute awarded a firm fixed-price purchase order to Invivoscribe, Inc. valued at $13,380.00 on March 12, 2021, for biological kits with an ultimate completion date of April 9, 2021. Work is performed in San Diego, California. No small business set-aside was used.</p>

<p>The National Cancer Institute awarded a purchase order to Invivoscribe, Inc. for $9,090 on July 18, 2018, with an ultimate completion date of July 18, 2019. Work is performed in San Diego, California. The order is priced on a firm fixed price basis for biological kits, reagents, and assays supporting the Molecular Diagnostics Laboratory's cancer research and diagnostics operations.</p>

<p>The National Cancer Institute awarded a purchase order to Invivoscribe, Inc. for $15,955.00 on March 18, 2020, for drugs and biologicals with an ultimate completion date of April 30, 2020. The order carries no small business set-aside. Work is performed in San Diego, California. The contract is firm fixed price, reflecting a commercial purchase of specialized biological kits and reagents to support cancer research initiatives.</p>

<p>The National Cancer Institute awarded a purchase order to Invivoscribe, Inc. for $13,380.00 on May 5, 2021, with completion by June 4, 2021. The order covers drugs and biologicals, specifically diagnostic and molecular testing materials for the institute's research operations. Performance takes place in San Diego, California.</p>

The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $17,210 firm fixed price purchase order to Invivoscribe, Inc. for biological kits. The place of performance is in San Diego, California. No set-aside designation was used for this contract. Invivoscribe will deliver the requested biological kits to the National Cancer Institute by April 22, 2024 to support the Institute's cancer research efforts. As the sole awardee, Invivoscribe will be...

<p>The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $12,038.04 firm fixed price purchase order to Invivoscribe, Inc. for assays. The place of performance is in San Diego, California and the completion date is January 31, 2024. As no set aside was used, the award was unrestricted. Invivoscribe will deliver the requested assays to support the National Cancer Institute's research efforts.</p>

This $17,355.82 firm fixed price purchase order was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute to the prime contractor Invivoscribe, Inc. (doing business as Invivoscribe Inc.), a for-profit manufacturer of precision diagnostics. The contract is for the delivery of biological kits, reagents, assays, and other molecular diagnostics products to support the National Cancer Institute's cancer research initiatives,...

This is a $18,370.00 firm fixed-price purchase order contract awarded by the National Cancer Institute (NCI), a civilian agency within the National Institutes of Health, to Invivoscribe, Inc., a for-profit manufacturer of biological products. The contract is for the delivery of &quot;BIOLOGICAL KITS&quot; and does not have a set-aside designation, indicating Invivoscribe competed for the award based on its specialized expertise. The contract has an ultimate completion date of April 26, 2025...

The Department of Health and Human Services' National Institutes of Health National Cancer Institute awarded a $16,000 purchase order to Invivoscribe, Inc. for biological reagents. Invivoscribe will provide the reagents to the National Cancer Institute under a firm fixed price contract executed on December 15, 2023 and concluding on January 31, 2024. The contract will be performed in San Diego, California by Invivoscribe, which specializes in reagents, kits, and services for clinical molecular...

<p>The National Cancer Institute awarded a purchase order to Invivoscribe, Inc. for $56,856.60 on July 2, 2026, under a Total Small Business set-aside. The order is for IGH+IGK clonality mega-ABI diagnostic materials and supplies, with performance in San Diego, California. Ultimate completion is scheduled for July 1, 2027. The contract carries firm fixed-price terms.</p>